Virtual Wards and the Diagnostics That Power Them

A community nurse parks on a terraced street at half past eight in the morning. In the boot of her car sits a soft bag of testing kit: a small handheld analyser, a strip of cartridges, a lancet, a control vial that has spent the night at whatever temperature the car park offered. Inside the house is a man in his seventies with a chest infection, breathless, being managed as an acute patient without ever leaving his own front room. She will take a sample, run a test on his kitchen table, and a number will appear. On that number, a doctor sitting in a hub several miles away will decide whether he stays at home tonight or is brought into hospital. The ward, in every sense that matters clinically, is that living room. The nearest thing to a laboratory is the kit in the boot of a car.

This is not a hypothetical. It is one of the largest shifts in how the NHS delivers care in a generation. Virtual wards, also called hospital at home, and urgent community response teams have gone from a few thousand beds to a national programme in the space of about three years, and they are genuinely useful: they let people receive acute-level care in their own homes, they ease pressure on hospital beds, and most patients would far rather be at home than on a trolley in a corridor. The best available evidence, a 2024 systematic review pooling sixty-nine studies, found these models carry a similar or lower risk of hospital readmission and no additional risk of death compared with a hospital bed. I am an enthusiast for the model. But there is a quiet dependency inside it that rarely gets the attention it deserves, and it is central to how the model works.

My argument is this. You cannot safely run an acute patient at home without the ability to measure them at home, and the moment you can measure them, you have moved a laboratory into the community whether you planned to or not. Virtual wards lean heavily on point-of-care testing. Yet in far too many virtual ward designs, the diagnostics and the quality governance around them are an afterthought, bolted on once the pathway is already live. Get the testing right and virtual wards are a triumph. Get it wrong and you have not saved anyone; you have simply relocated clinical risk from a monitored ward into an unmonitored living room.

What a virtual ward actually is, and why it is spreading

The idea is deceptively simple. Take a patient who would otherwise occupy a hospital bed, someone with a chest infection, a flare of heart failure, a frailty crisis, an infection that needs intravenous antibiotics, and manage them at home instead, with a remote clinical team providing oversight and a mix of in-person visits and remote monitoring. Urgent community response teams sit alongside this, responding within hours to people at risk of a hospital admission and trying to prevent it. NHS England has backed both as core parts of delivery, not fringe experiments, and the operational framework asks integrated care boards to run these services at scale.

The drivers are not hard to see. Beds are scarce and expensive. Deconditioning and hospital-acquired infection are real harms of admission, especially for older people. And the technology to keep a distant eye on someone, wearables, remote observations, video review, has matured to the point where close monitoring no longer requires a physical bay. The ambition was set out plainly in the 2022 planning guidance: 40 to 50 virtual ward beds for every 100,000 people by December 2023, backed by around 450 million pounds, which would have meant somewhere between 22,000 and 28,000 beds nationally, roughly a tenfold increase on where things stood at the end of 2021.

The reality has fallen well short of that, and it matters for the argument I am about to make. By October 2025 England had about 12,588 virtual ward beds, which works out at 19.7 per 100,000 population, less than half the ambition, and the number has barely moved for more than a year. Occupancy has crept up to just under 80 percent, which is the level the programme is chasing, but the capacity line has plateaued. The direction of travel is right, and I want to say that clearly before I complain about anything. What that plateau tells me is not that virtual wards are failing, but that we are still early, and being early is exactly when the diagnostics ought to be designed in, before volume makes retrofitting them painful.

But observations are not diagnostics. A pulse oximeter and a blood pressure cuff tell you how a patient is trending. They do not tell you the patient's potassium, their kidney function, their inflammatory markers, their blood gas, their clotting. And for an acute patient, those numbers are frequently the ones that decide the next move. Which is exactly where point-of-care testing walks onto the stage.

The diagnostics that quietly power the ward

Think about what a hospital does to an acute inpatient that a set of vital signs alone cannot replace. It takes bloods. It runs a gas. It checks renal function before the next dose of a nephrotoxic drug. It measures an infection marker to decide whether this is settling or escalating. It checks an INR before adjusting anticoagulation. It measures glucose in someone whose diabetes is being buffeted by acute illness. Move that patient home and none of those questions go away. What changes is only where, and by whom, the answer is generated.

This is not a vague aspiration. NHS England's own guidance for these services names the analytes it expects the kit bag to carry. For urgent community response, the core set is blood glucose and ketones, C-reactive protein, haemoglobin and haematocrit, lactate, a renal profile, and a venous blood gas. For virtual wards it adds D-dimer, influenza and COVID-19, INR, and, on heart failure wards, NT-proBNP. The virtual wards operational framework goes further and says staff kit bags should include portable in vitro point-of-care testing and point-of-care ultrasound so that assessments can be completed and decisions accelerated in the home. Read that list again. Every one of those is a laboratory analyte with a laboratory reference range and a laboratory failure mode, and it is now being generated on a kitchen table.

Point-of-care testing is what makes the whole thing possible. At the bedside-at-home, a virtual ward needs those results generated in minutes, without a sample making a round trip to a central laboratory that would take too long to inform a decision that has to be made now. This is the invisible engine of the model. Without it, a virtual ward is a monitoring service that can watch a patient deteriorate but cannot say why or how fast, and cannot act with confidence. The result has to close a loop: test taken at home, number transmitted, remote clinician reviews, decision made, patient managed, and round again, with quality governance wrapped around every stage.

A virtual ward without diagnostics is a monitoring service that can watch a patient deteriorate but cannot say why. The point-of-care test is the engine, not the accessory.

And here is the thing that ought to focus every commissioner's mind. The same NHS England guidance is explicit that this testing should sit under the remit of pathology. It states that pathology should have overall responsibility for the management of the devices and for oversight, that pathology should lead their validation to the required standards, register them for external quality assessment, and set the procedures for what happens when an internal quality control check fails. This is not a niche opinion held by a few quality obsessives. It is national guidance saying, in effect, that the laboratory does not stop being responsible just because the sample was taken on a sofa.

Who owns quality when the ward is a whole town?

This is the hard part, and it is the part that gets skipped. In a hospital laboratory, the accountability for a result is unambiguous. There is a named quality manager, a physical environment with controlled temperature, a competency file for every operator, a quality control regime run to a schedule, external quality assessment enrolment, and a documented chain from sample to signed-out result. Now scatter that ward across a town.

The devices no longer live in a controlled room. They live in cars, in cupboards, in kit bags, subject to heat, cold and vibration that a laboratory would never tolerate. The guidance itself is blunt about the consequence: a device that is not calibrated and maintained as the manufacturer sets out should not be used, and the strips and cartridges need storing to specification, sometimes in refrigerated or specialist kit bags. The operators are no longer a small trained team you can see; they are a mobile workforce of community nurses spread across shifts and geographies, and sometimes, increasingly, the patients themselves or their relatives. The results no longer travel down a corridor to a hub; they have to be transmitted, reliably and quickly, to a remote clinical team that may never physically meet the patient. Every one of the quiet assumptions that make laboratory governance work has been broken, not by carelessness, but by the geography of the model itself.

None of this is a criticism of the analyser. When point-of-care testing produces a misleading answer, the box is often not the culprit; the error tends to cluster upstream and downstream of it, in the sample and the operator, which is precisely what a laboratory quality system is built to police. A large UK evaluation of more than a hundred thousand near-patient tests on three venous-testing platforms found the chemistry was seldom the problem, yet the recorded error rates were far from trivial, and the single commonest fault on the infection-marker device was simply too little sample going in. That is a pre-analytical failure, and it is the kind of thing that is easier to catch when a trained team runs a bench in a fixed room than when a nurse runs a strip in an unfamiliar kitchen at the end of a long round.

So ask the awkward questions early. Who is accountable for the quality control on a device that lives in a nurse's car? Who confirms that a community nurse is still competent to run this test six months after their initial sign-off, when nobody is watching them do it? Who notices when a result never reaches the hub because a phone had no signal in a rural dead spot? Who owns the consumable that was stored above its rated temperature over a hot bank holiday weekend? If the honest answer to any of these is "nobody in particular", you do not have a virtual ward. You have an untested pathway that has not failed yet.

The standards did not move; only the address did

It is tempting to argue that a test done in a patient's home is a different, lighter category than a test done in a hospital. It is not, and the standards are unusually clear on this. The current international standard for medical laboratories, ISO 15189:2022, now brings point-of-care testing inside the laboratory quality standard itself, absorbing the older standalone POCT standard, ISO 22870, which has been withdrawn. The principles that make a result trustworthy, competency, quality control, external quality assessment and comparability of results across sites and devices, apply wherever the testing happens, even if the depth of the system is scaled to the setting. A potassium measured on a kitchen table and a potassium measured in a core laboratory are used to make the same kind of decision, and if we would not release the hospital one without governance behind it, we cannot rationally release the home one without it either.

Comparability deserves special emphasis in the virtual ward context. A patient may be tested on one handheld device during a home visit on Monday, a different device carried by a different nurse on Wednesday, and a hospital analyser if they are eventually admitted on Friday. If those devices do not agree, a genuinely stable patient can look like a deteriorating one, or worse, a deteriorating one can look stable. Harmonisation across the fleet is not a technical nicety. It is the difference between a trend you can trust and a trend that is an artefact of which box happened to be in the boot that day. This is one of the concrete reasons the guidance puts pathology in charge of the fleet: someone has to own the question of whether all these devices are telling the same story.

Ward pathway versus virtual ward pathway

The clearest way to see the challenge is to lay the two pathways side by side. In hospital, the diagnostic decision points, take the sample, run the test, review the result, decide, escalate, all happen inside one building with one accountable structure and a named owner at each step. In a virtual ward, the very same decision points still exist, but they are now distributed across a car, a living room, a mobile network and a remote hub, and the accountability at each step has to be deliberately assigned, because it no longer comes for free with the walls.

Nothing in that comparison is an argument against virtual wards. It is an argument for designing the diagnostics in from the first whiteboard sketch, rather than discovering, once volumes rise, that the pathway was built around a device nobody was formally governing. Retrofitting quality onto a live acute-at-home service is far harder, and far more dangerous, than building it in at the start.

Design the diagnostics in from day one

If you are commissioning, building or running a virtual ward or an urgent community response service, treat the testing and its governance as a founding component, not a later procurement line. Practical steps, in roughly the order I would take them:

• Choose devices for the environment, not the brochure. A device that performs beautifully on a laboratory bench may not tolerate a car boot in July. Select for ruggedness, temperature tolerance, ease of operation by a non-laboratory workforce, and the specific analytes your patient cohort actually needs, the blood gases, renal function, infection markers, INR, glucose and NT-proBNP that the national guidance itself names.
• Build connectivity in, so results are visible centrally. The guidance would prefer results to flow automatically into the record through middleware, and is clear that a lack of digital interoperability should not stop the testing, but that then someone has to key the number in by hand. Either way, design from the outset so that every test is transmitted to the hub, timestamped, attributed and visible to the clinical team that has to act on it, with a plan for what happens when a signal drops.
• Put a real competency framework behind a mobile workforce. Initial training against the instructions for use, an assessed sign-off, and, crucially, a way to reassess and re-evidence competency for people you cannot stand next to. The guidance expects training to be documented, kept current and updated over time. This is one of the hardest problems in the model, and it will not solve itself.
• Run quality control in the field, and make it enforceable. Define the frequency, decide how controls are stored and transported, record every result, and set a rule, the one the guidance asks pathology to write, that stops testing on a device when a control fails, wherever that device happens to be. A QC regime that is optional in the field is decorative.
• Write the escalation route down and rehearse it. Name who an abnormal result reaches, how fast, and who owns the decision to admit. In an acute-at-home service the escalation route is the safety net, and a net that exists only in principle is no net at all.
• Give pathology a seat at the design table. National guidance is not shy about this: pathology should have overall responsibility for the devices and their oversight. Bring them in on day one, not after the first near miss.

None of this requires turning a patient's living room into a hospital laboratory. It requires accepting that the ordinary, unglamorous discipline of laboratory medicine, competency, quality control, external quality assessment, comparability and escalation, has to travel with the ward when the ward leaves the building. If you want to understand which analytes carry which risks in a community setting, our analyte guides are a good starting point. Our training, including the free POCT Fundamentals course, is built for exactly the mobile, non-laboratory workforce these services depend on. And when you are standing a service up, our consultancy helps commissioners design the diagnostics and their governance in from the beginning, rather than bolting them on once the pathway is already carrying real patients.

The virtual ward is one of the best ideas in UK healthcare. Whether it consistently helps or quietly exposes patients depends heavily on a question nobody wants to own: who governs the test?

Move the ward home. Take the laboratory's discipline with it.

Virtual wards are not a fad, and they are not a compromise. Done well, they are better care in a better place, and I would not slow their spread for anything. But better care depends on trustworthy numbers, and a number you cannot trust can be worse than no number, because it is acted upon by a clinician who cannot see the patient. We have moved the ward into the living room. Now we have to move the laboratory's discipline in with it, deliberately, on day one, with a named owner for every result. That is not bureaucracy getting in the way of innovation. It is the discipline that lets the innovation be safe.

Sources and notes

This article draws on NHS England programme statistics and guidance, and on peer-reviewed and professional sources. Capacity and occupancy figures are from NHS England's monthly Virtual Ward Capacity and Occupancy SitRep, as reported through HTN Health Tech News; the beds-per-100,000 series in Figure 1 uses those published national figures, and the ambition band of 40 to 50 per 100,000 is the 2022/23 NHS planning target. The analyte panel in Figure 2 is taken directly from NHS England's guidance on integrating point-of-care diagnostics into these services. The loop in Figure 3 and the pathway comparison in Figure 4 are schematics that illustrate the argument rather than plotting a dataset. Statistics on capacity move month to month; the figures cited were current at the time of writing.

1. NHS England. Virtual wards. Overview of the hospital-at-home programme and the ambition to expand it.
2. NHS England. Integrating in vitro point of care diagnostics: guidance for urgent community response and virtual ward services. States that pathology should have overall responsibility for the devices and oversight, lead validation, register for external quality assessment and set procedures for failed internal quality control; lists the recommended analytes.
3. NHS England. Virtual wards operational framework. Sets the ambition for occupancy consistently above 80 percent and states that staff kit bags should include portable in vitro point-of-care testing and point-of-care ultrasound, and that patients should have access to tests as they would in hospital.
4. NHS England Digital. Virtual Ward Capacity and Occupancy statistics. The monthly national SitRep on capacity, occupancy and capacity per 100,000 population.
5. HTN Health Tech News. NHS England's December virtual ward update. December 2024: 12,733 beds, 75.4 percent occupancy, 9,602 patients on a virtual ward, 20.1 beds per 100,000; the best single ICB, Northamptonshire, reached 42.6 per 100,000.
6. HTN Health Tech News. Deep dive into virtual wards capacity and occupancy. October 2025: 12,588 beds, 19.7 beds per 100,000 GP-registered population, 79.8 percent occupancy.
7. The Lowdown. What are virtual wards and how are they being used?. The 2022 planning guidance ambition of 40 to 50 beds per 100,000 by December 2023, around 450 million pounds of funding, and roughly 22,400 to 28,000 beds nationally.
8. Shi C and colleagues. Inpatient-level care at home delivered by virtual wards and hospital at home: a systematic review and meta-analysis. BMC Medicine, 2024. Sixty-nine studies (38 randomised, n=6,413; 31 non-randomised, n=31,950); similar or lower readmission risk and no additional mortality risk versus inpatient care, low-certainty evidence.
9. Fanshawe and colleagues. Pre-analytical error for three point-of-care venous blood testing platforms in acute ambulatory settings. PLOS One, 2020. Most recorded point-of-care error was pre-analytical, with insufficient sample the largest single cause on the C-reactive protein device.
10. International Organization for Standardization. ISO 15189:2022, Medical laboratories, requirements for quality and competence, which now brings point-of-care testing inside the laboratory quality standard, superseding the withdrawn ISO 22870.